Authors' recommendations: Vaccination is an effective intervention against rotavirus gastroenteritis. However, it is also related with considerable costs. Based on study assumptions and using NOK 500 000 as threshold for cost-effective interventions, it is unlikely that routine vaccination against rotavirus will be cost-effective from a healthcare perspective (approximately 14 % and 2,5 ‰ for Rotarix® and Rotateq®, respectively). However, by adopting a societal perspective, including indirect costs due to production losses, the conclusion was changed to vaccination being considered cost-effective with a probability of approximately 94 % for Rotarix® and 4 % for Rotateq®. From a societal perspective there was also a decent probability of vaccination being deemed as cost saving to society (about 39 %). The analyses do not provide clear answers of which of the two vaccine candidates to be preferred. This must be addressed after potential bidding rounds have been completed and final vaccine prices are available.

Project Status: Completed

URL for project: http://www.kunnskapssenteret.no/Publikasjoner/8170.cms?language=english&threepage=1

Year Published: 2009

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Norway

Organisation Name: Norwegian Institute of Public Health

Contact Address: Universitetsgata 2, Postbox 7004 St. Olavs plass, NO-0310 Oslo NORWAY. Tel: +47 23 25 50 00; Fax: +47 23 25 50 10;

Contact Name: Berit.Morland@nokc.no, dagny.fredheim@nokc.no

Contact Email: Berit.Morland@nokc.no, dagny.fredheim@nokc.no

Copyright: Norwegian Knowledge Centre for the Health Services (NOKC)